Agenda

Agenda correct at time of going to press

26 October 2011

19.00

Drinks for early arrivals and early registration

 

27 October 2011

08.00 Registration Opens

10.00

Welcome

10.15 Session: Investment in CE Life Science

Chair: Marcin Szumowski

10.15

Talk: A perspective on life science and life science investment in CE

Roland Kozlowski

10.45

Talk: What’s best suited to the CE investor: devices, services, diagnostics or pharmaceuticals

Michał Kostka; South Moravian Innovation Centre (Czech Republic)

11.15

General Comments on the global picture and potential of CE and New Perspectives on EU grant funding for life sciences

Oliver Murphy and Michał Turczyk; Deloitte (Poland)

11.15 Coffee

12.15

 

 

Panel Discussion: General and CE specific challenges facing investors in life sciences

 

Moderator: Roland Kozlowski

 

Robert Rzemiński; MCI (Poland)

 

Martin Oxley, UKTI (UK/Poland)

 

Martin Fusek; IOCB TTO (Czech Republic)

 

Marcell Veidner; Hungarian Biotech Association (Hungary)

13.00 Lunch


14.10 Session: Attracting investment and clients from beyond CE

Chair: Martin Oxley (UKTI)

14.10

Talk: Pharmaceutical venture funds what is the general expectation what are the thoughts on Central Europe

Graeme Martin; Takeda Research Investment (US)

14.40

Talk: What were your considerations for developing a business in the CE region

Quintiles; Wojciech Przybyś (Poland)

15.10

Panel Discussion: Attracting venture financing from abroad, what will investors look for?

 

Moderator: Martin Oxley

 

Quintiles; Wojciech Przybyś (Poland)

 

Sander van Deventer, Forbion (Netherlands)

 

Simon Kerr, Imperial Innovations (UK)

 

Jonathan Hepple, Seroba-Kernel (UK/Ireland)

16.00 Tea

16.30

ession: Private & young company presentations

 

Chair: Marcin Szumowski

 

BTM Sp. z o. o. (Marcin Szumowski; Poland)

 

Proteon Sp. z o. o. (Jarosław Dastych; Poland)

 

Hependo Sp. z o. o. (Łukasz Kutrzeba; Poland)

 

Biovectis (Krzystof Kucharczyk; Poland)

 

BBS Nanotechnology (Janos Borbely; Hungary)

 

Flavopharma Sp. z o. o. (Mikołaj Gurdała; Poland)

18.00

Close for Day

19.00

Conference Dinner and networking drinks

28 October 2011

09.00 Session: Public Markets in Central Europe

Chair: Oliver Murphy

09.00

Talk: New Connect: its mission

Emil Stępień; Polish Stock Exchange (Poland)

09.30

Talk: Case studies from a New Connect Nominated Advisor

Artur Chabowski; Acadia (Poland)

10.00

Panel Discussion: Challenges for public market investment in CE Life Sciences

Moderator: Oliver Murphy

Artur Chabowski; Acadia (Poland)

Emil Stępień; Polish Stock Exchange (Poland)

Simon Wallwork, Semple Fraser LLP (UK)

Emma Palmer Foster, EJ Palmer Consulting (UK)

Piotr Czapski; EQT Partners (Poland)

10.45 Coffee

11.15

Recent life science listings on Poland’s alternative investment market: New Connect

Selvita (Poland); Paweł Przewięźlikowski CEO

Medicalgorithmics (Poland); Marek Dziubiński CEO

11.45

Business in Krakow

Paweł Węgrzyn; “Local Government Entrepreneurship Advisor”

12.00

Panel Discussion: The way forward for the CE sector: lessons learnt from more mature markets

Moderator: Roland Kozlowski

Tadeusz Pietrucha; Biotech Consulting (Poland)

Peter Neubeck; TVM (Germany)

Piotr Lassota; Polpharma (Poland)

Grazianno Seghezzi; Sofinnova (France)

Paweł Błachno; JCI (Poland)

12.45

Statement on Life Science in Poland

Leszek Grabarczyk ; The National Centre for Research & Development

13.00

Summing up

Roland Kozlowski; (LSBC) & Oliver Murphy (Deloitte)

13.15 Conference Close